Stem Cell Therapy Market - By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics) & Global Forecast, 2023-2032
Published on: 2024-08-01 | No of Pages : 240 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Stem Cell Therapy Market - By Type (Allogenic Stem Cell Therapy, Autologous Stem Cell Therapy), By Therapeutic Area (Oncology, Orthopedic, Cardiovascular, Neurology), End-use (Hospitals, Clinics) & Global Forecast, 2023-2032
Stem Cell Therapy Market Size
Stem Cell Therapy Market size was valued at over USD 11.8 billion in 2022. Driven by the increasing occurrence of chronic ailments across the globe, the market is anticipated to grow at over 10% CAGR from 2023 to 2032.
Increasing incidence of chronic disorders such as muscular dystrophy, neurological ailments, cancer, and others in both developed and developing economies is proliferating the demand for advanced experimental medical treatment. The US reported over 608,570 deaths due to cancer and nearly 1.9 million newly diagnosed cases of the disease in 2021 alone. Such high case loads are creating a notable impetus for stem cell-based therapy, fostering stem cell therapy market progress.
Over time, conventional drugs and treatments have demonstrated an efficacy drop when treating chronic ailments such as cancer. Stem cell-based therapies, although still considered experimental, are regarded highly promising when it comes to treating such ailments. In fact, treatments such as mesenchymal stem cell therapy have been proven efficacious in treating inflammatory, degenerative, and autoimmune disorders due to their regenerative potential and immunoregulatory properties.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Stem Cell Therapy Market Size in 2022 | USD 11.8 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 10% |
| 2032 Value Projection | USD 31.5 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 120 |
| Tables, Charts & Figures | 241 |
| Segments covered | Type, Therapeutic area, End-use, and Region |
| Growth Drivers | |
| Pitfalls & Challenges |
Ethical considerations in stem cell therapy may constrain industry development
Despite an expanding scope for product adoption, the ethical challenges linked to stem cell therapies may impede the stem cell therapy market expansion. At present, the derivation of pluripotent stem cell lines from oocytes and embryos is a highly sensitive issue of contention. There are certain risks associated with such therapies including immune rejection of the cells used in treatment. The risks during stem cell transplantation include inappropriate stem cell migration, and tumor formation, among others. Meanwhile, the demand for such therapies is also limited due to medical concerns associated with oocyte retrieval and other complications related to experimental procedures.
Stem Cell Therapy Market Analysis
Based on therapeutic area, stem cell therapy market from orthopedic segment is expected to grow at over 9.5% CAGR from 2023 to 2032, fueled by the surging occurrence of orthopedic ailments among the elderly population. Therapeutic or treatment procedures that incorporate stem cells are believed to have the potential to facilitate faster healing of bone and cartilage defects. These regenerative therapies work for various orthopedic complications such as osteoarthritis, focal and cartilage damage among others, and effectively eliminate the need for invasive surgeries where the geriatric population have a historically low success and survival rate.
In terms of end use, stem cell therapy market size from hospitals segment held a valuation of over USD 6.5 billion in 2022, supported primarily by growing government focus on healthcare infrastructure upgradation efforts. In October 2022, for instance, the US government announced an investment of around USD 110 million to improve access to healthcare in rural areas. A majority of the proposed capital would be going towards the construction of new hospitals. Numerous academic and research institute-affiliated hospitals aid R&D initiatives that advance the field of stem cell therapy further. The connection with such institutes helps hospitals advance stem cell treatment therapies.
Europe stem cell therapy market valuation is poised to surpass USD 8 billion by 2032, owing to the increasing occurrence of neurodegenerative diseases in the region. Stem cell therapies involving MSCs and iPSCs have been shown to be effective in treating several neurodegenerative diseases such as Alzheimer’s disease (AD), and Parkinson’s disease (PD) among others. As such, many healthcare professionals in Europe are increasingly turning to cellular therapy for treating neurodegenerative ailments such as AD, PD, traumatic brain injury, and other conditions where neurological disabilities cannot be reversed. As per the UK government, over 700,000 people in the UK are suffering from Alzheimer’s disease, which is creating an acute need for cellular therapy.
Stem Cell Therapy Market Share
The leading stem cell therapy market players include
- FUJIFILM Cellular Dynamics, Inc.
- Novadip Biosciences
- DiscGenics
- Mesoblast Ltd.
- GSK plc.
- ThermoGenesis Holdings, Inc.
- MEDIPOST Co., Ltd.
Many of these players are focusing on capacity expansion initiatives to increase their market footprint. For instance, in May 2022, Japanese multinational pharmaceutical company, Takeda Pharmaceutical Company Limited, inaugurated Ireland’s first stem cell center in Grange Castle. The facility will aid the distribution of cell therapy treatment options to patients in US, EU, and Canada.
Impact of COVID-19 Pandemic
The COVID-19 pandemic did not affect stem cell therapy industry significantly. Given that the focus of many research and government bodies was on discovering quick and efficient ways for treating and preventing deadly illnesses such as COVID-19, the market experienced much activity. In fact, the pandemic was also responsible for giving the push needed to kick off regenerative medicine clinical trials globally. Many clinical trials were able to confirm that MSC therapy could be a potential treatment for COVID-19 patients, specifically those with acute respiratory distress syndrome. As per ClinicalTrial.gov, mesenchymal stem cells were also used to ascertain the safest and most efficient method for treating COVID-19.
This stem cell therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
By Type
- Allogenic stem cell therapy
- Autologous stem cell therapy
By Therapeutic Area
- Oncology
- Orthopedic
- Cardiovascular
- Neurology
- Orthopedic
- Others
By End-use
- Hospitals
- Clinics
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Russia
- Poland
- Switzerland
- Netherlands
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Singapore
- Thailand
- Latin America
- Brazil
- Argentina
- Mexico
- Chile
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Israel